Pegylated arginine deiminase reversed dyslipidemia, hepatic steatosis, and inflammation in obese mice by promoting mammalian energy expenditure and insulin sensitivity, which depends on the hepatocyte-specific FGF21.105. Here, FGF21 is linked to metabolic syndrome.